Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer - Full Text View

Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus Cancer

This study is not yet open for participant recruitment.
Verified by University of Tennessee, June 2006

Sponsors and Collaborators:	University of Tennessee North American Skull Base Society
Information provided by:	University of Tennessee
ClinicalTrials.gov Identifier:	NCT00347256

Purpose

The purpose of this study is to determine the efficacy of concurrent chemotherapy and radiotherapy pre-operatively in patients with advanced paranasal sinus cancer. The main objectives of this study are: 1) to measure the rate of complete response to preoperative chemoradiation and 2) to study the efficacy of combining preoperative chemoradiation and surgery in terms of local control of the cancer two years post treatment.

Condition	Intervention
Paranasal Sinus Neoplasms	Drug: cisplatin Procedure: targeted radiation therapy Procedure: tumor resection

MedlinePlus related topics:

Cancer

ChemIDplus related topics:

Cisplatin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study

Official Title:	Preoperative Radiotherapy and Concomitant Chemotherapy Followed by Surgery for Advanced Paranasal Sinus Carcinoma

Further study details as provided by University of Tennessee:

Primary Outcome Measures:

Local control of cancer at two years post treatment
Response to preoperative chemoradiation

Secondary Outcome Measures:

Estimation of the proportion of the inoperable tumors which become operable after chemoradiation
Identification of factors that are associated with inoperability
Estimation of the overall survival and cumulative incidence of death due to disease at 2 years
Determination of the acute and long-term toxicity, particularly ophthalmologic complications, and surgical morbidity associated with this regimen
Measurement of the accuracy of conventional imaging techniques (CT, MRI) compared with the addition of PET imaging in predicting the response to chemoradiation therapy.

Estimated Enrollment:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Karnofsky Performance Score: >= 60
Creatinin clearance >= 50 ml/min or serum creatinine =<1.5 mg/dl
Total bilirubin, AST, ALT =< 1.5 X laboratory uln
ANC >= 2000/mm3, platelets >= 100,000/mm3
Serum calcium within normal range
T3 or T4 state tumors of paranasal sinuses
Squamous cell carcinoma, adenocarcinoma, high-grade mucoepidermoid carcinoma, sinonasal undifferentiated carcinoma

Exclusion Criteria:

History of other malignancy in the last 3 years
Other serious comorbidity that may significantly reduce the survival in next 5 years
Pregnant or lactating women
History of radiation to the head and neck region
Paranasal sinus tumor is recurrent after prior treatment
Presence of cervical node metastasis
Presence of distant metastasis
Advanced nasopharyngeal malignancy with sphenoid or posterior ethmoid invasion

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00347256

Contacts


Contact: Sandeep Samant	901-448-5885	ssamant@utmem.edu

Contact: Priscilla Adler	901-516-2763	padler@utmem.edu

Locations


United States, Tennessee
	University of Tennessee Health Science Center	Not yet recruiting
	Memphis, Tennessee, United States, 38104
	Principal Investigator: Sandeep Samant, MS, FRCS

Sponsors and Collaborators

University of Tennessee

North American Skull Base Society

Investigators


Study Chair:	Sandeep Samant, MS, FRCS	University of Tennessee Health Science Center

Principal Investigator:	Sandeep Samant, MS, FRCS	University of Tennessee Health Science Center

More Information

North American Skull Base Society webpage This link exits the ClinicalTrials.gov site

Study ID Numbers:	NASBS-PNS001
First Received:	June 29, 2006
Last Updated:	June 29, 2006
ClinicalTrials.gov Identifier:	NCT00347256
Health Authority:	United States: Department of Health and Human Services; United States: Food and Drug Administration